Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,581.00
(
1.15%
)
US TECH 100
23,567.20
(
1.22%
)
Dow Jones
46,208.47
(
1.38%
)
Brent Oil
100.58
(
3.91%
)
Bitcoin
70,472.00
(
-0.60%
)
News Focus
News Focus
Post# of 257273
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122807
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 165404

Wednesday, 03/18/2015 6:10:51 AM

Wednesday, March 18, 2015 6:10:51 AM

Post# of 257273
AZN’s LABA/LAMA combination for COPD succeeds in phase-3 trials:

http://in.reuters.com/article/2015/03/18/us-astrazeneca-copd-idINKBN0ME0LT20150318

The drug, which AstraZeneca acquired after buying Pearl Therapeutics two years ago [#msg-88847837], combines a long-acting beta-2 agonist (LABA) and a long-acting muscarine antagonist (LAMA). AstraZeneca plans to file PT003 for approval commencing in 2015.

Rival firms also have LAMA/LABA drugs that are more advanced than PT003, but AstraZeneca's drug is administered with a pressurized metered-dose inhaler instead of a dry-powder inhaler, which may suit elderly patients in particular.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today